aTENSION.life

life GmbH specializes in hypertension management, offering innovative diagnostic solutions to enhance patient care and improve clinical workflows.life GmbH, founded in 2024 in Vienna, Austria, focuses on advancing hypertension care through novel diagnostic platforms.life is focused on advancing hypertension care through its core product, the ALDO+ testing platform, which utilizes mass spectrometry to provide precise diagnostics for hypertension management. This innovative testing solution allows for the direct measurement of key hormones such as Angiotensin I, Angiotensin II, and Aldosterone from a single blood sample, offering critical insights into the Renin-Angiotensin-Aldosterone System (RAAS). The ALDO+ platform is especially significant for identifying primary aldosteronism, a common form of secondary hypertension that often goes undiagnosed due to inadequate screening rates. The company's products target healthcare professionals, including clinicians and laboratories, aiming to improve diagnosis and treatment plans for hypertensive patients.20 per test, which can be privately paid by patients or potentially reimbursed through private insurance. The company employs a Prep ‘n’ Ship™ model, allowing laboratories without mass spectrometry capabilities to collect and prepare samples on-site before sending them to specialized labs for analysis. This model fosters partnerships with clinical laboratories and healthcare providers, enhancing diagnostic capabilities while creating additional income streams for those involved. The company plans to expand its current offerings and introduce new products aimed at further enhancing hypertension diagnostics. Specific new products are currently in the design phase, with targeted geographic expansion into additional European and North American markets planned for the coming years.

1. Seed

   Apr 10, 2025

   Amount

   $3M

   Investors

   Locked